Based on recent comments from Elon Musk, Neuralink seems to be considering an “upgrade” for its first human patient, allowing him to perform even more sophisticated tasks using only his mind. 

Elon Musk’s recent comments

Musk’s update came as a reply to an X post that featured some details about the current activities of Noland Arbaugh, the first person in the world to receive a Neuralink implant. Since receiving his implant, Arbaugh has been able to take back his life, and he now games, attends class, and even works as a paid speaker. 

In his response, Musk stated that Arbaugh could also be the first Neuralink patient to receive an upgrade. “Noland might be the first to receive a Neuralink upgrade and/or dual Neuralink implant to further augment his abilities. It won’t be long before a Neuralink recipient can beat most and eventually all humans at fast reaction video games,” Musk wrote in a post on X.

Noland’s recent update

Noland actually provided a quick update about his life with his Neuralink implant, which he fondly named Eve, on X. He noted that his direct involvement with Neuralink has lessened as more participants have joined the company’s human trials. And despite a recent pressure sore setback, he remains optimistic and teased “big news” coming for his two-year update in early 2026.

Beyond his recovery, Arbaugh stated that Neuralink has made everyday goals achievable again. He is currently studying neuroscience, taking chemistry, biology, and pre-calculus and maintaining good grades, something he said would have been impossible without Neuralink.

The post Neuralink’s first patient could receive an upgrade: Elon Musk appeared first on TESLARATI.

Arbaugh, who became paralyzed after a diving accident, stated that his Neuralink implant, which he fondly calls “Eve,” continues to transform his daily life.

Arbaugh celebrates Neuralink’s progress

In his post on X, Arbaugh revealed that his hands-on involvement with Neuralink has decreased as more participants have joined the program. “The team might call me to test something once in a blue moon,” he wrote, adding that he’s happy to see others experience the technology’s full potential, from operating robotic arms to typing on keyboards with thought alone.

He credited Neuralink and Elon Musk for giving him “the opportunity to be the first,” as the experience has been life-changing. Despite a recent pressure sore that temporarily kept him bedridden, Arbaugh noted that he is still very optimistic, describing his journey as one of resilience, faith, and gratitude. He also teased “big news” coming for his two-year update in early 2026.

Studies and a growing public speaking career 

These days, Arbaugh stated that he is focused on his studies in neuroscience, taking full-semester courses in chemistry, biology, and pre-calculus while earning top grades. He credited “Eve” for making school possible again, as his current academic workload would have been “impossible without Neuralink.” Arbaugh stated that he has also begun building a speaking business after delivering a paid talk at Fortune’s Brainstorm Tech conference.

“At the beginning of September I attended the Fortune Brainstorm Tech conference in Park City, Utah, as a paid speaker. That sentence seemed like an impossibility two years ago. But it’s just the beginning. My business is built, my legal is near complete, I’m surrounding myself with a team of amazing folks, and I plan on speaking once or twice a month in the same fashion beginning as soon as January. 

“Conferences, interviews, podcasts—you name it, and I want to be there spreading the word about how amazing this technology is, the growth it’s experiencing, the possibilities of the future, and how it has so deeply affected my life,” Arbaugh stated.

The post Neuralink’s first human patient reflects on 21 months with brain implant “Eve” appeared first on TESLARATI.

The news marks a noticeable step in Musk’s expanding presence in the Bay Area, despite the move of his biggest companies, Tesla and SpaceX, to Texas.

Neuralink’s Bay Area expansion

As noted in a report from the San Francisco Business Times, the property that Neuralink has leased is located at 499 Forbes Boulevard, and it was built by Aralon Properties before it was leased to cancer test developer InterVenn Biosciences. The site, however, had remained vacant since 2023 after InterVenn canceled its 10-year lease.

xAI, Musk’s artificial intelligence startup, is reportedly scouting for an even larger Bay Area office as well, as noted in a report from the San Francisco Chronicle. Combined, the two ventures could secure nearly 400,000 square feet of local workspace, a move seen as a symbolic return of sorts for Musk-led innovation to Silicon Valley.

Neuralink’s momentum

Founded in 2016, Neuralink develops brain-computer interfaces intended to help paralyzed patients control digital devices through thought. The company received U.S. regulatory approval in 2023 to begin human trials, with its first patient, quadriplegic Noland Arbaugh, making headlines for his stunning ability to control a computer cursor and play games using only his mind. Since receiving his implant, Arbaugh has stated that he now browses the web, plays video games like Mario Kart, studies neuroscience, and operates his smart home without lifting a finger. 

Nauralink is only just getting started, with Elon Musk noting on X that the company is busy preparing its next product, Blindsight, for human trials. As per Musk, Neuralink is “aiming to restore (limited) sight to the completely blind next year,” an aggressive target for a potentially life-changing device.

The post After moving Tesla to Texas, Elon Musk is back in the Bay Area with Neuralink expansion appeared first on TESLARATI.

Paralyzed from the shoulders down following a 2016 swimming accident, Arbaugh underwent a two-hour robotic surgery that implanted Neuralink’s Telepathy device into his motor cortex. This has allowed him to control devices and even play video games using only his mind.

A new kind of independence

Since the implant, Arbaugh has reclaimed daily activities that were once impossible. He browses the web, plays video games like Mario Kart, studies neuroscience, and operates his smart home without lifting a finger, according to The Valley Vanguard. Though the device requires periodic charging, Arbaugh views the trade-off as minor compared to the independence it provides. 

Arbaugh described his life before his Neuralink surgery as “a blur of meaningless time.” Today, he spends up to ten hours a day using the chip to learn and connect with others. He has gone back to school, diving deep into neuroscience, and he has also discovered a new purpose through public speaking. 

He does not hesitate to share his story with audiences worldwide. “It feels like I’ve been given a second shot,” he said. “I always had potential, now I have a way to express it.”

Challenges and a vision

Being the first Neuralink patient has not been without strain. Arbaugh has faced intense media scrutiny, online harassment, and even a dangerous SWAT incident at his home triggered by a hoax call, as noted in a Forbes report. Still, he remains a vocal supporter of the technology, funding his advocacy through speaking events and public outreach.

Founded by Tesla and SpaceX CEO Elon Musk, Neuralink’s goal is to connect human thought seamlessly with tech devices, potentially restoring communication and mobility for those living with paralysis or other conditions. Arbaugh’s success with his Telepathy device offers a tangible demonstration of what’s possible, and as per Elon Musk, Neuralink is now preparing to roll out its Blindsight device, which should be capable of restoring sight to the visually impaired.

The post Neuralink’s first human patient shares journey to renewed self-independence appeared first on TESLARATI.

The trial was approved by the FDA under an investigational device exemption, and it could help pave the way for people with speech impairments to communicate more quickly and efficiently.

Thought-to-text technology

The upcoming trial aims to read speech directly from the brain, enabling participants to transmit words without moving their mouths or using a keyboard, as noted in a report from Bloomberg News.

DJ Seo, Neuralink’s president, told an audience at the Korea Foundation for Advanced Studies in Seoul that the company hopes to demonstrate communication with large language model AI platforms “at the speed of thought,” potentially faster than spoken speech.

“We think that it’s actually possible to demonstrate abilities to speak to the latest AI model, or LLM models, at the speed of thought, even faster than how you’re speaking, and being able to potentially get that information back through your AirPods, effectively closing the loop,” Seo stated.

Production ambitions

Ultimately, Seo described the trial as a stepping stone toward broader human enhancement and consumer-facing applications, beyond the company’s initial focus on medical conditions like ALS, stroke, blindness, and Parkinson’s disease.

While initial implants will focus on patients with severe speech impairments, Neuralink plans to eventually expand to healthy individuals by 2030. The company aims to scale to 20,000 implants per year by 2031.

“We’re currently envisioning a world where, in about 3 to 4 years, there will be someone who’s otherwise healthy who’s going to get a Neuralink. If you’re imagining saying something, we would be able to pick that up,” the executive noted.

The post Neuralink is planning to launch US trials translating thoughts into text appeared first on TESLARATI.

The executive posted the update on social media platform X amid news of Neuralink’s first successful Telepathy implants outside the United States. 

Blindsight trials

In a response to a post from Neuralink’s official X account about its first Canadian patients, Musk wrote that the company is “Aiming to restore (limited) sight to the completely blind next year.” The update was well-received on social media, as the device would most likely provide notable quality of life improvements to patients. Neuralink’s current implant, Telepathy, is already changing lives today, and the same will likely be true for Blindsight.

This was not the first time that Musk has provided an update to Neuralink’s Blindsight trials. Earlier this year, Musk told the Qatar Economic Forum that the first human implantation of Blindsight could occur early 2026, potentially in the United Arab Emirates. Neuralink has explored collaboration with the Cleveland Clinic Abu Dhabi to perform the initial surgery. Blindsight has also received a “breakthrough device” designation from the US FDA, hinting at the implant’s development.

Blindsight’s potential

Musk has previously described Blindsight as Neuralink’s brain-computer interface (BCI) designed to restore vision. During Neuralink’s 2022 Show & Tell event, Musk stated that Blindsight would target the brain’s visual cortex, bypassing damaged eyes entirely to generate visual perception. This means that vision could be restored even for people who were born blind. 

“The first two applications we’re going to aim for in humans are restoring vision, and I think this is notable in that even if someone has never had vision ever, like they were born blind, we believe we can still restore vision. The visual part of the cortex is still there. Even if they’ve never seen before, we’re confident they could see,” Musk said.

The post Elon Musk: Neuralink could restore partial vision to the blind next year appeared first on TESLARATI.

The operations mark Neuralink’s first international expansion of its clinical trial program.

A new step in Neuralink’s trials

The surgeries were performed at Toronto Western Hospital. The two patients, both in their early 30s from Ontario and Alberta, underwent the procedures on August 27 and September 3 under the leadership of neurosurgeon Dr. Andres Lozano. Both patients were implanted with Neuralink’s first device, Telepathy, which allows users to interact with tech devices using only their thoughts.

Lozano noted that the effects were visible almost immediately. “The first patient was able to control a cursor by just thinking within minutes. It is extremely rapid. The signals are decoded and the artificial intelligence reads the signals and then translates them into movement on the cursor,” he said. “They just think about it and it happens.” 

Both men were discharged the day after surgery, as noted in a CBC report.

Clinical trials, safety, and quality of life

The Canadian patients will be monitored for at least a year, with the research team permitted to enroll up to four additional participants with either spinal cord injuries or Amyotrophic Lateral Sclerosis (ALS). The trial will focus on safety and quality-of-life improvements, and doctors will be watching for potential side effects such as seizures, infections, or strokes.

Over the coming months, the patients are expected to advance from moving a cursor to typing on a virtual keyboard using only their thoughts. “It’s really as a preliminary step to see whether this should be scaled and rolled out to a larger population. The device right now is a cursor, but in the future you could drive a car, you could drive your wheelchair, you could drive a robot,” Lozano stated.

The post Neuralink expands beyond US with breakthrough brain chip implants in Canada appeared first on TESLARATI.

Now, the company has completed a new first, bringing more hope to the future of this revolutionary technology.

Neuralink’s third brain chip patient shares first video edited with BCI

Neuralink revealed in an update on Monday morning that it has officially completed two implants in a single day, with Patients 8 and 9 both receiving devices over the past weekend.

“Both participants are recovering well and in great spirits,” the company said in the short update. It did not disclose which day the surgeries were completed, but it did state explicitly that they both occurred on the same day:

We successfully completed both P8 and P9 this weekend, our first time performing two surgeries in one day. Both participants are recovering well and in great spirits. We are looking forward to supporting them on their Neuralink journey.

— Neuralink (@neuralink) July 21, 2025

Musk said that Neuralink’s capabilities could do “life-changing good for ultimately millions, maybe billions, of people.” Right now, it is being used to help combat life-altering diseases, such as ALS, also known as Lou Gehrig’s Disease, as well as cervical spinal cord injuries.

Eventually, Neuralink could resolve things like anxiety, depression, and blindness, among many other ailments.

Its Link device also received FDA recognition for speech restoration earlier this year, marking a significant bit of progress in the program as it explores ways to cure ailments of various natures.

The post Elon Musk’s Neuralink posts massive update with new milestone appeared first on TESLARATI.

During Elon Musk’s interview at the Qatar Economic Forum, he announced that Neuralink aims to implant its Blindsight brain-to-computer interface (BCI) device in a human patient by late 2025 or early 2026.

Blindsight focuses on restoring vision. A few years ago, Musk mentioned that Neuralink’s BCI devices would restore vision for people, even those born blind.

“The first two applications we’re going to aim for in humans are restoring vision, and I think this is notable in that even if someone has never had vision ever, like they were born blind, we believe we can still restore vision. The visual part of the cortex is still there. Even if they’ve never seen before, we’re confident they could see,” Musk said during Neuralink’s Show & Tell in 2022. 

Musk said Blindsight could be implanted into a human patient in the United Arab Emirates (UAE). Neuralink plans to partner with the Cleveland Clinic Abu Dhabi to implant the first human patient with Blindsight.

Elon Musk’s neurotechnology company is partnering with the Cleveland Clinic Abu Dhabi to conduct the first clinical trial of the UAE-PRIME study. Like Neuralink’s PRIME study in the United States, UAE-PRIME will focus on human patients with motor and speech impairments.

Neuralink received Food and Drug Administration (FDA) approval to conduct the PRIME and CONVOY studies in the United States. PRIME tests the capabilities of the company’s Link implant to restore or enable motor and speech in participants. Meanwhile, the CONVOY study explores Link’s ability to control assistive robotic devices. Neuralink already has an assistive robotic arm called ARA that could expand patients’ autonomy beyond smart devices.

Blindsight would probably require a separate study from PRIME and CONVOY. As such, Neuralink might need FDA approval in the United States to start human trials for Blindsight. However, Blindsight already received a “breakthrough device” designation from the US FDA.

In April 2025, Neuralink opened its patient registry to participants worldwide. The neurotechnology company has already implanted its Link BCI device into five patients. Earlier this year, Neuralink welcomed one of its first PRIME study participants as the first patient in its CONVOY study.

The post Neuralink Blindsight human trials expected to start in the UAE appeared first on TESLARATI.

Neuralink’s brain-computer interface (BCI) device, Link, has secured the U.S. Food and Drug Administration’s (FDA) “breakthrough” designation for restoring communication in patients with severe speech impairment. This milestone advances Elon Musk’s vision of merging human cognition with technology.

The Link device targets individuals with neurological conditions like Amyotrophic Lateral Sclerosis (ALS), stroke, spinal cord injury, cerebral palsy, and multiple sclerosis. In a recent X video, Neuralink’s third PRIME Study participant, Bradford G. Smith, who lives with ALS, showcased the device’s potential.

Using Link, Smith regained his ability to communicate, leveraging AI to narrate with a synthesized version of his former voice. “I am typing this with my brain,” Smith wrote. “It is my primary communication.”

Smith edited the X video with the help of Link. In the video, he demonstrated how Link enabled him to control a computer cursor to communicate, highlighting the BCI’s ability to interface with external devices.

Before Link, Smith relied on an eye tracker, which limited communication in bright settings and restricted his mobility. Now, Neuralink’s implant enables him to connect more freely. His experience shows Neuralink’s progress in empowering paralyzed individuals and those with neurodegenerative diseases through revolutionary assistive solutions.

The company is also exploring applications for vision restoration and other health challenges. In 2024, Neuralink received the FDA’s ‘breakthrough device’ tag for its Blindsight device. Elon Musk explained that Blindsight would help people who have lost both eyes and function in their optic nerve to see. However, Neuralink’s current focus remains on mobility and communication.

Neuralink recently expanded its patient registry to include participants worldwide. The PRIME Study, likely the primary target for new registrants, tests Link’s base capabilities. Meanwhile, the CONVOY study explores Link’s ability to control robotic devices, like an assistive robotic arm. This broader access underscores Neuralink’s commitment to scaling its trials.

The company is reportedly preparing for a $500 million funding round, with preliminary talks valuing Neuralink at $8.5 billion pre-money and potentially $9 billion post-money, though terms remain fluid. Neuralink has not commented on the speculation about funding.

By earning FDA breakthrough status, Neuralink positions Link as a transformative tool for those with severe speech impairments. Smith’s experience illustrates its potential to restore independence, while ongoing trials and funding efforts signal the company’s ambition to redefine human-technology interaction for neurological conditions and beyond.

The post Neuralink device gets FDA recognition for speech restoration appeared first on TESLARATI.